Acute myeloblastic leukemia with t(8;21) following Philadelphia positive acute lymphoblastic leukemia.

abstract：:Follicular lymphoma is a low grade malignancy characterized by the translocation t(14;18), which involves the putative oncogene bcl-2. We describe a 73-year-old patient presenting with Burkitt acute lymphoblastic leukemia (B-ALL) L3 (Burkitt type), whose cells had the following immunophenotype: CD19+, CD22+, HLA-DR+, ...

journal_title：Leukemia

authors： Brito-Babapulle V,Crawford A,Khokhar T,Laffan M,Matutes E,Fairhead S,Catovsky D

更新日期：1991-01-01 00:00:00

abstract：:Reduced-intensity conditioning (RIC) regimens have been increasingly used as an alternative to conventional myeloablative conditioning (MAC) regimens for elderly patients, for patients medically infirm to qualify for conventional allogeneic stem cell transplantation (SCT), and for disorders in which traditional MAC-SC...

journal_title：Leukemia

authors： Jiménez M,Ercilla G,Martínez C

更新日期：2007-08-01 00:00:00

abstract：:We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epi...

journal_title：Leukemia

authors： Lee YK,Shanafelt TD,Bone ND,Strege AK,Jelinek DF,Kay NE

更新日期：2005-04-01 00:00:00

abstract：:We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: ...

journal_title：Leukemia

authors： Sobh M,Michallet M,Gahrton G,Iacobelli S,van Biezen A,Schönland S,Petersen E,Schaap N,Bonifazi F,Volin L,Meijer E,Niederwieser D,El Cheikh J,Tabrizi R,Fegeux N,Finke J,Bunjes D,Cornelissen J,Einsele H,Bruno B,Pott

更新日期：2016-10-01 00:00:00

abstract：:Synergistic molecular vulnerabilities enhancing hypomethylating agents in myeloid malignancies have remained elusive. RNA-interference drug modifier screens identified antiapoptotic BCL-2 family members as potent 5-Azacytidine-sensitizing targets. In further dissecting BCL-XL, BCL-2 and MCL-1 contribution to 5-Azacyti...

journal_title：Leukemia

authors： Bogenberger JM,Kornblau SM,Pierceall WE,Lena R,Chow D,Shi CX,Mantei J,Ahmann G,Gonzales IM,Choudhary A,Valdez R,Camoriano J,Fauble V,Tiedemann RE,Qiu YH,Coombes KR,Cardone M,Braggio E,Yin H,Azorsa DO,Mesa RA,Ste

更新日期：2014-08-01 00:00:00

abstract：:In the present study, 89 patients with generalized immunocytoma were analyzed retrospectively for the prognostic influence of clinical features and of immunophenotype using bone marrow biopsies. Univariate analysis selected the following variables as significant for survival: age over 60 years (p = 0.021), Rai and Bin...

journal_title：Leukemia

authors： Eisterer W,Hilbe W,Fend F,Ludescher C,Falk M,Thaler J

更新日期：1995-02-01 00:00:00

abstract：:All-trans-retinoic acid (ATRA) is highly active in acute promyelocytic leukemia but not in other types of acute myeloid leukemia (AML). Previously, we showed that ATRA in combination with Lysine-specific demethylase 1 (LSD1) inhibition by tranylcypromine (TCP) can induce myeloid differentiation in AML blasts. This pha...

journal_title：Leukemia

authors： Wass M,Göllner S,Besenbeck B,Schlenk RF,Mundmann P,Göthert JR,Noppeney R,Schliemann C,Mikesch JH,Lenz G,Dugas M,Wermke M,Röllig C,Bornhäuser M,Serve H,Platzbecker U,Foerster KI,Burhenne J,Haefeli WE,Müller LP,Bind

更新日期：2020-06-19 00:00:00

abstract：:Monitoring of BCR-ABL transcripts has become established practice in the management of chronic myeloid leukemia. However, nucleic acid amplification techniques are prone to variations which limit the reliability of real-time quantitative PCR (RQ-PCR) for clinical decision making, highlighting the need for standardizat...

journal_title：Leukemia

authors： Saldanha J,Silvy M,Beaufils N,Arlinghaus R,Barbany G,Branford S,Cayuela JM,Cazzaniga G,Gonzalez M,Grimwade D,Kairisto V,Miyamura K,Lawler M,Lion T,Macintyre E,Mahon FX,Muller MC,Ostergaard M,Pfeifer H,Saglio G,Saw

更新日期：2007-07-01 00:00:00

abstract：:The predominant usage of VH4-34 and V3-21 and reports of stereotyped CDR3s suggest a shared antigenic target of B-cell receptors (BCR) from mantle cell lymphomas (MCL). To identify the target antigens of MCL-BCRs, BCRs from 21 patients and seven MCL cell lines were recombinantly expressed and used for antigen screenin...

journal_title：Leukemia

authors： Thurner L,Hartmann S,Fadle N,Kemele M,Bock T,Bewarder M,Regitz E,Neumann F,Nimmesgern A,von Müller L,Pott C,Kim YJ,Bohle RM,Wasik M,Schuster SJ,Hansmann ML,Preuss KD,Pfreundschuh M

更新日期：2019-01-01 00:00:00

abstract：:The NUP214-ABL1 fusion kinase has recently been identified in 6% of patients with T-cell acute lymphoblastic leukemia. In contrast to the more common oncogenic ABL1 fusion BCR-ABL1, NUP214-ABL1 localizes to the nuclear pore complexes and has attenuated transforming properties in hematopoietic cells and in mouse bone m...

journal_title：Leukemia

authors： De Keersmaecker K,Versele M,Cools J,Superti-Furga G,Hantschel O

更新日期：2008-12-01 00:00:00

abstract：:The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at levels below the landmark of complete cytogenetic remission. Quantification of BCR-ABL transcripts has proven to be the most sensitive method available, and has ...

journal_title：Leukemia

authors： Müller MC,Cross NC,Erben P,Schenk T,Hanfstein B,Ernst T,Hehlmann R,Branford S,Saglio G,Hochhaus A

更新日期：2009-11-01 00:00:00

abstract：:Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies,...

journal_title：Leukemia

authors： Wen T,Wang J,Shi Y,Qian H,Liu P

更新日期：2020-10-29 00:00:00

abstract：:In 2005, the first guidelines were published on the management of patients with multiple myeloma (MM). An expert panel reviewed the currently available literature as the basis for a set of revised and updated consensus guidelines for the diagnosis and management of patients with MM who are not eligible for autologous ...

journal_title：Leukemia

authors： Palumbo A,Sezer O,Kyle R,Miguel JS,Orlowski RZ,Moreau P,Niesvizky R,Morgan G,Comenzo R,Sonneveld P,Kumar S,Hajek R,Giralt S,Bringhen S,Anderson KC,Richardson PG,Cavo M,Davies F,Bladé J,Einsele H,Dimopoulos MA,Sp

更新日期：2009-10-01 00:00:00

abstract：:This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1-4...

journal_title：Leukemia

authors： Richardson PG,Hofmeister CC,Raje NS,Siegel DS,Lonial S,Laubach J,Efebera YA,Vesole DH,Nooka AK,Rosenblatt J,Doss D,Zaki MH,Bensmaine A,Herring J,Li Y,Watkins L,Chen MS,Anderson KC

更新日期：2017-12-01 00:00:00

abstract：:CD13/aminopeptidase N (APN) is a cell surface metallopeptidase expressed by normal and leukemic myeloid cells, and by lymphoblasts in 5-10% of acute lymphoid leukemia (ALL) cases, previously classified as 'biphenotypic' or 'mixed-lineage' leukemias. In fresh cells from two early B-lineage, t(9;22)-positive, ALL cases ...

journal_title：Leukemia

authors： Saito M,Kumagai M,Okazaki T,Nakazawa S,Shapiro LH,Look AT,Campana D

更新日期：1995-09-01 00:00:00

abstract：:In the past years, the genomes of thousands of tumors have been elucidated. To date however, our knowledge on somatic gene alterations in normal cells is very limited. In this study, we demonstrate that tetanus-specific human memory B lymphocytes carry a substantial number of somatic mutations in the coding regions of...

journal_title：Leukemia

authors： Slot LM,Wormhoudt TAM,Kwakkenbos MJ,Wagner K,Ballering A,Jongejan A,van Kampen ACM,Guikema JEJ,Bende RJ,van Noesel CJM

更新日期：2019-05-01 00:00:00

abstract：:Novel techniques were used to detect which cell lineages were affected by monosomy 7 in a patient who had myelodysplastic syndrome and later developed acute leukemia. The patient had had paroxysmal nocturnal hemoglobinuria for 20 years before developing refractory anemia with excess of blasts. Cytogenetic analysis at ...

journal_title：Leukemia

authors： Kere J,Knuutila S,Ruutu T,Leskinen R,de la Chapelle A

更新日期：1988-02-01 00:00:00

abstract：:Fludarabine phosphate (2-F-ara-AMP) is an adenine nucleoside analogue that shows significant activity against chronic lymphocytic leukemia and indolent lymphoma. We assessed the cytotoxic interaction produced by the combination of the active metabolite of fludarabine phosphate, fludarabine (9-beta-D-arabinofuranosyl-2...

journal_title：Leukemia

authors： Kano Y,Akutsu M,Tsunoda S,Suzuki K,Ichikawa A,Furukawa Y,Bai L,Kon K

更新日期：2000-03-01 00:00:00

abstract：:Recently, it has been clarified that interaction between hematopoietic cells and endothelial cells is important in normal hematopoiesis and leukemogenesis. In this study, we examined the relationship between AML cells and endothelial cells by analyzing the expression profile of angiogenic factors, angiopoietin-1 (Ang-...

journal_title：Leukemia

authors： Watarai M,Miwa H,Shikami M,Sugamura K,Wakabayashi M,Satoh A,Tsuboi K,Imamura A,Mihara H,Katoh Y,Kita K,Nitta M

更新日期：2002-01-01 00:00:00

abstract：:Basic fibroblast growth factor (bFGF) is a pleiotropic cytokine which has recently been shown to delay fludarabine-induced apoptosis in B cell chronic lymphocytic leukemia (B-CLL) cells. To investigate the potential mechanism of bFGF-mediated delay of apoptosis, two EBV-transformed B prolymphocytic cell lines (JVM-2, ...

journal_title：Leukemia

authors： König A,Menzel T,Lynen S,Wrazel L,Rosén A,Al-Katib A,Raveche E,Gabrilove JL

更新日期：1997-02-01 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) is a progressive disease in which chemotherapy may result in temporary suppression of the peripheral blood lymphocyte count, but cure is not usually possible. Drug resistance mechanisms and the multidrug resistant (MDR) phenotype may be relevant to the therapeutic response. We have s...

journal_title：Leukemia

authors： Holmes JA,Jacobs A,Carter G,Whittaker JA,Bentley DP,Padua RA

更新日期：1990-03-01 00:00:00

abstract：:Abnormalities of several cell-cycle regulatory genes including cyclin D1, p16CDKN2 and p15CDKN2B have been described in B cell non-Hodgkin's lymphoma (B-NHL). We describe a new B-NHL cell line (Granta 519), with concurrent abnormalities of the cyclin D1, pl6CDKN2 and pl5CDKN2B genes. An independent clinical case of ma...

journal_title：Leukemia

authors： Jadayel DM,Lukas J,Nacheva E,Bartkova J,Stranks G,De Schouwer PJ,Lens D,Bartek J,Dyer MJ,Kruger AR,Catovsky D

更新日期：1997-01-01 00:00:00

abstract：:The ubiquitin-proteasome system is an important regulator of cell growth and apoptosis. The potential of specific proteasome inhibitors to act as novel anti-cancer agents is currently under intensive investigation. Several proteasome inhibitors exert anti-tumour activity in vivo and potently induce apoptosis in tumour...

journal_title：Leukemia

authors： Almond JB,Cohen GM

更新日期：2002-04-01 00:00:00

abstract：:Between August 1978 and September 1982, 642 patients with newly diagnosed acute myelogenous leukemia (AML) were entered onto a Southwest Oncology Group Study which addressed four questions. (i) What is the comparative utility of rubidazone versus adriamycin in remission induction? (ii) What is the role of prophylactic...

journal_title：Leukemia

authors： Morrison FS,Kopecky KJ,Head DR,Athens JW,Balcerzak SP,Gumbart C,Dabich L,Costanzi JJ,Coltman CA,Saiki JH

更新日期：1992-07-01 00:00:00

abstract：:Hematopoietic stem cell transplantation is becoming an increasingly important approach to treatment of different malignant and non-malignant disorders. There is thus growing demand for diagnostic assays permitting the surveillance of donor/recipient chimerism posttransplant. Current techniques are heterogeneous, rende...

journal_title：Leukemia

authors： Lion T,Watzinger F,Preuner S,Kreyenberg H,Tilanus M,de Weger R,van Loon J,de Vries L,Cavé H,Acquaviva C,Lawler M,Crampe M,Serra A,Saglio B,Colnaghi F,Biondi A,van Dongen JJ,van der Burg M,Gonzalez M,Alcoceba M,Bar

更新日期：2012-08-01 00:00:00

abstract：:Purified blast cells from peripheral blood of 12 patients, with chronic myelogenous leukemia (CML) in chronic phase, were analyzed for the constitutive expression of the granulocyte-macrophage colony-stimulating factor (GM-CSF) transcript. Seven out 12 patients exhibited the specific 1.0 kb GM-CSF mRNA. Six from these...

journal_title：Leukemia

authors： Lajmanovich A,Berthier R,Schweitzer A,Leger J,Hollard D

更新日期：1993-08-01 00:00:00

abstract：:Eight new cases (five adults and three children) of acute leukemia characterized by the presence in bone marrow cells of a t(4;11)(q21;q23)and one similar case, a child, with a t(1;11)(p32;q23) are reported. All patients were diagnosed as having acute lymphoblastic leukemia (ALL) with high-risk features. Immunological...

journal_title：Leukemia

authors： Hagemeijer A,van Dongen JJ,Slater RM,van't Veer MB,Behrendt H,Hählen K,Sizoo W,Abels J

更新日期：1987-01-01 00:00:00

abstract：:A widely accepted definition of resistance or intolerance to hydroxyurea (HU) in patients with essential thrombocythemia (ET) is lacking. An international working group (WG) was convened to develop a consensus formulation of clinically significant criteria for defining resistance/intolerance to HU in ET. To this aim, ...

journal_title：Leukemia

authors： Barosi G,Besses C,Birgegard G,Briere J,Cervantes F,Finazzi G,Gisslinger H,Griesshammer M,Gugliotta L,Harrison C,Hasselbalch H,Lengfelder E,Reilly JT,Michiels JJ,Barbui T

更新日期：2007-02-01 00:00:00

abstract：:The major cause of early death in acute promyelocytic leukemia (APL), the high risk of a bleeding diathesis is now successfully counteracted within a few days by differentiation therapy using ATRA. Moreover, no resistance to this drug has been recorded during induction when the usual presence of PML/RAR alpha was conf...

journal_title：Leukemia

authors： Degos L

更新日期：1994-01-01 00:00:00

abstract：:The wt1 gene is located on chromosome 11p13 and encodes a zinc finger motif-containing transcription factor involved in regulation of growth and differentiation. Its expression was shown during embryonic development in various tissues as well as in a few human malignancies including acute leukemias. Using RT-PCR, we f...

journal_title：Leukemia

authors： Menssen HD,Renkl HJ,Rodeck U,Maurer J,Notter M,Schwartz S,Reinhardt R,Thiel E

更新日期：1995-06-01 00:00:00